NCT06253442

Brief Summary

A Comparative study Between Ultrasound guided Interscalene Block and Combined Ultrasound guided suprascapular and axillary nerve blocks for proximal humerus fracture Surgeries. The aim of this study is to investigate whether (Suprascapular nerve block) and (Axillary nerve block) are effective in providing analgesia for shoulder surgery as an (Interscalene block), while minimizing the occurrence of hemi-diaphragmatic paralysis. We hypothesized that analgesia with a (Suprascapular nerve block and Axillary nerve block) would be noninferior compared with patients receiving an interscalene block and the incidence of hemi-diaphragmatic paralysis would be significantly lower with (Suprascapular nerve block and Axillary nerve block) in proximal humerus fracture surgeries.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 30, 2024

Completed
11 days until next milestone

Study Start

First participant enrolled

February 10, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 12, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2024

Completed
Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

6 months

First QC Date

January 30, 2024

Last Update Submit

September 13, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • Individual visual analog pain scores (VAS) at 0, 6, 12 and 24 h postoperatively (VAS; 0 = no pain and 10 = worst pain imaginable).

    Individual visual analog pain scores (VAS) at 0, 6, 12 and 24 h postoperatively (VAS; 0 = no pain and 10 = worst pain imaginable).

    24 HOURS

  • The presence of moderate-to-severe pain, defined as visual analog pain scores (VAS) 4 or greater during the first 24 h postoperative.

    The presence of moderate-to-severe pain, defined as visual analog pain scores (VAS) 4 or greater during the first 24 h postoperative.

    24 HOURS

  • Time to first reported pain and first analgesic request during post-anesthesia care unit stay (in minutes).

    Time to first reported pain and first analgesic request during post-anesthesia care unit stay (in minutes).

    24 HOURS

  • Analgesic consumption during surgery, in post-anesthesia care unit, and during the first 24 h post-surgery.

    Analgesic consumption during surgery, in post-anesthesia care unit, and during the first 24 h post-surgery.

    24 hours

Study Arms (2)

Patients will receive Supra scapular nerve block and Axillary nerve block.

ACTIVE COMPARATOR

ultrasound guided suprascapular nerve block combined with ultrasound guided axillary nerve block will be provided to the patient

Procedure: Patients will receive Supra scapular nerve block and Axillary nerve block.

Patients will receive Interscalene block.

ACTIVE COMPARATOR

ultrasound guided interscalene brachial plexus block will be provided to the patient

Procedure: Patients will receive Interscalene block.

Interventions

Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood. For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique.

Patients will receive Supra scapular nerve block and Axillary nerve block.

Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.

Patients will receive Interscalene block.

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients American Society of anesthesiologists' physical status (ASA) I to II.
  • Aged 18 to 65 years.
  • Both sexes.
  • Patients scheduled for proximal humerus fracture surgeries.

You may not qualify if:

  • Patient refusal
  • ASA physical status III or more.
  • Patients with known allergy to any of the study drugs.
  • Infection at the site of injection.
  • Patients with history of cardiovascular disease.
  • Patients with renal disease.
  • Patients with hepatic disease.
  • Patients with neuromuscular disease.
  • Presence of any coagulopathy.
  • Chronic opioid, gabapentin or pregabalin use.
  • Patients with history of any psychiatric disorder.
  • BMI more than 35 kg/m2.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University

Cairo, Abbasia, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

January 30, 2024

First Posted

February 12, 2024

Study Start

February 10, 2024

Primary Completion

August 15, 2024

Study Completion

August 15, 2024

Last Updated

September 19, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations